IPM Take
Menstrual migraine has been common enough to be familiar and neglected enough to have no specifically approved preventive treatment. That contradiction says something about which neurological burdens health systems have historically been willing to normalise.
The Phase III LUNA result is therefore bigger than another CGRP trial. Atogepant was tested around the biological window in which attacks occur, rather than asking patients to fit a generic continuous-treatment model. Personalised medicine should look exactly like this: treatment shaped around how disease actually behaves
Executive Summary
AbbVie reported positive topline results from the Phase III LUNA trial of atogepant for menstrual migraine. The 468-participant study evaluated treatment for seven consecutive days beginning three days before menstruation over three menstrual cycles.
Atogepant reduced perimenstrual migraine days by an average of 1.20 days from baseline, compared with 0.40 days with placebo, producing a placebo-adjusted reduction of 0.80 days, p<0.0001. The trial also met all eight ranked secondary endpoints, including measures of headache burden, acute medication use, disability and cognitive function.
The safety findings were reported as consistent with atogepant’s established profile. These remain company-reported topline data and have not yet been published as a complete peer-reviewed Phase III dataset.
Why it matters
- Patients / advocates: Predictability does not make menstrual migraine less disabling; it simply makes the lost days easier to anticipate.
- Clinicians: Intermittent prevention could create a more tailored option for patients whose attacks cluster around menstruation.
- Regulators: The programme could support the first treatment indication designed specifically around menstrual migraine.
- Payers: Reimbursement rules should not force continuous treatment if a targeted intermittent approach proves effective.
Migraine medicine has become increasingly sophisticated while menstrual migraine has remained strangely easy to treat as a footnote. The attacks are linked to a predictable biological window, but predictability has often been used as an excuse to tell women to organise around the disease rather than build care around it.
LUNA reverses that logic. Atogepant was administered for seven days around menstruation, targeting the period in which the patient’s risk was greatest. The study then measured not just migraine days, but medication use, disability and cognitive function, all areas that determine whether an attack actually disrupts life.
That makes the result politically interesting. The intervention is tailored to the timing of disease rather than forcing the patient into the timetable of treatment. It is an unusually clear example of personalisation that does not require genomic sequencing or expensive infrastructure.
The full dataset still matters, particularly for effect size, durability and subgroup performance. But if the topline findings survive scrutiny, the field will have a difficult question to answer: why did a predictable and disabling neurological condition affecting women have to wait so long for a trial built specifically around it?
